CDNA News & Events

CareDx announced on April 15 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end of the third quarter of 2026. CareDx's Lab Products business consists of IVD PCR kits for rapid deceased donor HLA typing, IVD NGS-based kits for transplant recipient HLA typing globally, including AlloSeq Nano; and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

CareDx introduced AlloSeq Nano, a nanopore-based HLA and ABO blood type genotyping solution, at the European Federation for Immunogenetics Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high-resolution HLA genotyping in under three hours with streamlined long-read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution. In early access testing, Alloseq Nano's single-step amplification and prep workflow required approximately 45 minutes of hands-on time to assay eleven HLA loci plus ABO in a single test. The assay's elegant probe redundancy helps minimize allele dropout, while long-read sequencing reduces phasing ambiguities, enhancing overall performance and accuracy. AlloSeq Nano expands CareDx's pre-transplant Lab Products portfolio, alongside AlloSeq Tx and QTYPE, to support a broader range of laboratory throughput requirements and use cases. To introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23, from 13:00-14:00 BST, at the Edinburgh Congress Centre, Sidlaw Auditorium. The symposium will feature scientific and educational discussions related to AlloSeq Nano and CareDx's transplant diagnostics portfolio. CareDx will also present multiple abstracts at EFI 2026 reflecting scientific engagement across laboratory, clinical, and technical dimensions of transplant diagnostics. Accepted abstracts include presentations featuring AlloSeq cfDNA in kidney and lung transplant settings, as well as a presentation featuring QTYPE, highlighting rapid ABO genotyping in combination with HLA typing.

New records highs in the S&P 500 and Nasdaq Composite indices - along with a retreat in the Vix index to the lowest level since the start of the U.S.-Iran conflict - suggest that investors are looking through the geopolitical uncertainty.  Instead, with more large banks reporting constructive results, including Morgan Stanley'sQ1 beat this morning that sent the stock to all-time highs, the markets are positioning for further risk-on flows.  Tech was the standout sector on Wednesday, with beaten down Software names extending their strong performance this week, followed by Consumer Cyclicals and Communication Services, whereas Basic Materials and Industrials - areas of refuge throughout the AI disruption narrative - underperformed.In the opening hour of the evening session, U.S. equity futures are flat, though WTI Crude Oil remains under pressure near $90.  FT report of a potential ceasefire between Israel and Lebanon - a sticking point in the U.S.-Iran negotiation process - is continuing the theme of de-escalation in the Middle East.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -J.B. Huntup 1.8%ALSO HIGHER -CareDxup 8.4% after Q1 pre-announcement, Lab Products divestmentVoyager Technologiesup 8.1% after NASA order announcementPPG Industriesup 5.0% after positive Q1 pre-announcement, price increaseEuroseasup 2% after contract extension for EM KeaConagra Brandsup 1.0% on insider buying activityDOWN AFTER EARNINGS -MIND Technologydown 16.8%SL Green Realtydown 2.5%Home BancShares, Inc.down 1.4%ALSO LOWER -QuidelOrthodown 18.9% after below-consensus Q1 pre-announcementFord Motordown 1% after departure of EV executive

Reports preliminary Q1 Testing Service Volume roughly 54,900, up 17% year-over-year.